GlassScriptPhysician profile
Inchel Yeam
NPI 1346341344
$2,724.20
in general payments reported to CMS, 2019-2025
26 companies · $583 in 2025
The $583 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $123 · 2020: $131 · 2022: $426 · 2023: $890 · 2024: $572 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,884 · Consulting Fee: $150 · Education: $10.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,883.59 |
| Consulting Fee | $150.00 |
| Education | $10.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $723.94 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.75 | 2022-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Jazz Pharmaceuticals INC. | $263.51 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $243.20 | 2022-2024 | Fasenra, Breztri |
| Harmony Biosciences LLC | $223.91 | 2022-2024 | Wakix |
| Novo Nordisk INC | $120.00 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $118.59 | 2019-2025 | Gardasil 9, M-M-R II, Capvaxive |
| Amgen INC. | $101.15 | 2022-2023 | Tezspire |
| Exact Sciences Corporation | $73.24 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Fisher & Paykel Healthcare INC | $70.28 | 2022 | |
| Idorsia Pharmaceuticals US INC | $51.09 | 2023-2024 | Quviviq |
| Neurocrine Biosciences, INC. | $49.33 | 2022-2025 | |
| Alk-Abello, INC | $48.66 | 2025 | Neffy |
| Ucb, INC. | $42.03 | 2024 | Rystiggo |
| Lilly USA, LLC | $40.95 | 2023-2025 | Jardiance, Emgality, Mounjaro |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $35.68 | 2025 | |
| Ani Pharmaceuticals, INC. | $27.33 | 2025 | Purified Cortrophin Gel |
| Mayne Pharma Commercial LLC | $26.83 | 2022 | |
| Dexcom, INC. | $25.37 | 2023 | Dexcom G6 Transmitter |
| Avadel Cns Pharmaceuticals, LLC | $24.65 | 2025 | Lumryz |
| Kaleo, INC. | $21.93 | 2022 | |
| Medtronic USA, INC. | $21.61 | 2019 | |
| Abbvie INC. | $20.78 | 2023 | Botox |
| Lucid Diagnostics INC. | $20.57 | 2022 | |
| Allergan, INC. | $16.98 | 2020 | |
| Sunovion Pharmaceuticals INC. | $15.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inchel Yeam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.